Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study

Nonproteinuric diabetic kidney disease

(2020) Masayuki Yamanouchi et al.   Clinical and Experimental Nephrology

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)

(2020) Masaomi Nangaku et al.   Kidney International Reports

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

(2020) David C Wheeler et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study

(2019) Satoshi Iimuro et al.   Clinical and Experimental Nephrology

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

(2019) Hiddo J L Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Guidelines for clinical evaluation of chronic kidney disease

(2018) Eiichiro Kanda et al.   Clinical and Experimental Nephrology

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

(2018) Hiddo J. L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Baseline characteristics and enrichment results from the SONAR trial

(2018) Hiddo J.L. Heerspink et al.   DIABETES OBESITY & METABOLISM

The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis

(2018) Masayuki Yamamoto et al.   PHYSIOLOGICAL REVIEWS

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference

(2017) Colin Baigent et al.   KIDNEY INTERNATIONAL

Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl

(2014) Melanie P. Chin et al.   JOURNAL OF CARDIAC FAILURE

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

(2013) Stacey Ruiz et al.   KIDNEY INTERNATIONAL

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

(2013) Dick de Zeeuw et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress

(2011) Michael B. Sporn et al.   JOURNAL OF NATURAL PRODUCTS

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

(2011) Pablo E. Pergola et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study

(2010) M. E. Molitch et al.   DIABETES CARE

Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled Trial

(2009) Tadao Akizawa et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES